A fast growing genetically engineered salmon is a good bet for approval by the Food and Drug Administration. It would be the first genetically modified animal sold as food. Dubbed “Frankenfish” by opponents, the new version of Atlantic salmon was developed by AquaBounty Technologies. It grows almost twice as fast as farm-raised salmon, thanks to one growth hormone gene from a chinook salmon and another from an eel, the ocean pout. The application has been pending before the agency for well over 10 years.
A congressional effort to ban the fish will fail, although it’s a fair bet that lawmakers will give the FDA the authority to require a label identifying the produce as genetically modified. “Approval of genetically modified salmon, the first such hybrid to be considered for human consumption, is unprecedented, risky and a threat to the survival of wild species,” says Sen. Mark Begich, D-Alaska, whose state has a thriving salmon industry.
Also likely to be on the table: Broadening the mission of regulators to ensure they consider environmental risks before granting future approvals -- not just whether the food is safe and whether animals are harmed by the genetic manipulation.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
A push to add greater public input to the approval process is also a good bet. The current procedure is similar to that for new drugs, with limited public participation. “The current process is confidential. It’s not transparent or participatory,” says Gregory Jaffe of the Center for Science in the Public Interest.
Next up: The Enviropig -- a porker genetically altered to make the manure it produces less polluting, with phosphorus levels 30% to 65% lower than normal. It’s being developed by scientists at the University of Guelph in Canada. Also in the works from Hematech Inc. are cattle that are not susceptible to mad cow disease. The animals lack a protein that mutates, so they don’t get the disease and can’t pass it on.
-
Trump-Era Regulations Will Ease Access to CryptoThe Kiplinger Letter The president wants to make the U.S. the leader in digital assets.
-
I missed the 2-Year IRMAA Rule. Now, my Medicare costs are skyrocketing. What are my options?A spike in income could result in costly IRMAA charges on your Medicare premiums. We ask financial planning experts for advice.
-
Trump-Era Regulations Will Broaden Access to Crypto
The Kiplinger Letter The president wants to make the U.S. the leader in digital assets.
-
How to Adopt AI and Keep Employees HappyThe Kiplinger Letter As business adoption of AI picks up, employee morale could take a hit. But there are ways to avoid an AI backlash.
-
The Rise of AI: A Kiplinger Special ReportThe Kiplinger Letter Our special report looks at the opportunities and challenges of generative AI and how its rapid move into the mainstream is impacting every aspect of our lives.
-
Big Changes Are Ahead for Higher EdThe Kiplinger Letter A major reform of higher ed is underway. Colleges are bracing for abrupt change, financial headwinds and uncertainty.
-
AI-Powered Smart Glasses Set to Make a Bigger SplashThe Kiplinger Letter Meta leads the way with its sleek, fashionable smart glasses, but Apple reportedly plans to join the fray by late 2026. Improved AI will lure more customers.
-
Breaking China's Stranglehold on Rare Earth ElementsThe Letter China is using its near-monopoly on critical minerals to win trade concessions. Can the U.S. find alternate supplies?
-
Things that Surprise Business Owners When It’s Time to SellThe Kiplinger Letter When it’s time to retire and enjoy the fruits of growing their business, owners are often surprised by how tough it is to give up their baby!
-
What New Tariffs Mean for Car ShoppersThe Kiplinger Letter Car deals are growing scarcer. Meanwhile, tax credits for EVs are on the way out, but tax breaks for car loans are coming.
